Sign in
CompletedNo phase

Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

Key facts

Who runs it
Abionic SA
Where
Chicago, Lexington, Providence, and Toledo, United StatesSee the 5 sites
Trial code
Status
Completed
People taking part
544 people enrolled
Started
10 Dec 2019
Ended
28 Dec 2023
Type of study
Observational
Treatments tested
  • Blood sampling
Record updated
30 January 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • 1. Provision and understanding of signed and dated written informed consent by patient or legally designated representative prior to any mandatory study-specific procedures, sample collection, or analysis
  • 2. Male or female, aged ≥ 18 years
  • 3. Admitted to ICU on the day of screening, with expectation that patient will require ICU management for a minimum of 24 hours

Who cannot take part

  • 1. Expected to die within 24 hours no matter what therapy is given, from the time of screening
  • 5. Previous ICU admission during this hospital stay
  • 2. Suffering on ICU admission or study entry from or known acute or chronic pancreatitis or pancreatic cancer)
  • 3. Admitted to ICU due to elective cardiac surgery with an uncomplicated stay anticipated
  • 6. Confirmed COVID-19 as reason for ICU admission
  • 4. Patients having a valid Do Not Resuscitate order

Where in United States

  • Northwestern UniversityChicago, United States
  • Rush University Medical CenterChicago, United States
  • University of KentuckyLexington, United States
  • Rhode Island HospitalProvidence, United States
  • Mercy Health St. VincentToledo, United States

About the trial

What the trial wants to find out

This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at risk of sepsis as an aid in identifying sepsis.

The group in the trial

  • Device: Blood sampling

    Treatment: Blood sampling

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Prospective, Biomarker-result-blinded Observational Study Evaluating Immunoassay Measurements of Pancreatic Stone Protein Performed on Abionic's abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
Publications
Record updated
30 January 2024